GLP-1 drugs are no longer limited to diabetes care. In a some years, they have become the fastest-growing drug category in pharmaceutical history. Drugs like Ozempic, Wegovy, and Mounjaro are driving high demand in global markets. Analysts expect the anti-obesity drug market to cross USD 100 billion by the early 2030s. GLP-1 agonists are expected to drive most of that growth. For pharma, biotech investors and healthcare systems, the conversation is bigger than weight loss. Market competition, pipeline expansion, pricing pressure, and long-term treatment demand are becoming major strategic problems.
What Are GLP-1 Drugs and Why Are They Dominating the Market?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs that mimic a natural hormone that is involved in appetite, insulin secretion and blood sugar control. These medications were originally developed to treat type 2 diabetes. Today, they are widely prescribed for obesity and weight management. Older obesity drugs usually delivered around 5–8% body weight reduction. Newer GLP-1 therapies are showing average reductions of nearly 15–22%. This level of weight loss is helping expand insurance reimbursement and mainstream adoption. Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound are key to the GLP-1 market size forecast and semaglutide market growth.
GLP-1 Market Size & Growth Forecast 2025–2034
The GLP-1 market size forecast continues to expand as obesity treatment demand rises worldwide. The global anti-obesity medication market was valued at USD 52.82 billion in 2025. It is projected to reach USD 133.92 billion by 2034, growing at a CAGR of 10.9% from 2026 to 2034. The obesity drug market 2025 outlook is bright with the obesity rates continuing to rise globally. GLP-1 therapies are being used well beyond diabetes care. WHO 2024 data shows nearly 1 in 8 adults worldwide are living with obesity. In the US obesity rates have already topped 40% among adults.
The anti-obesity drug market is led by North America. High obesity rates, strong insurance coverage, and faster prescription adoption support market growth. Asia-Pacific is the fastest-growing regional market. Rising healthcare access and obesity awareness are supporting growth across the region. Manufacturing capacity still remains a major challenge. Novo Nordisk and Eli Lilly are investing billions to expand production and meet rising demand.
For full market sizing data, segment-level forecasts, and regional analysis, access Polaris Market Research’s GLP-1 and Anti-obesity medication Report.
Competitive Landscape — Who's Winning the GLP-1 Race?
|
Company |
Key Drug(s) |
Strategic Position |
|
Novo Nordisk |
Ozempic, Wegovy |
Market leader with nearly 50% market share. Supply constraints are still limiting additional growth. |
|
Eli Lilly |
Mounjaro, Zepbound |
Fast follower becoming a co-leader. Stronger weight-loss efficacy data has increased market attention. |
|
Amgen |
MariTide |
Phase 3 pipeline candidate focused on muscle preservation during weight loss. |
|
Pfizer |
Danuglipron |
Oral GLP-1 candidate. Positioned as a major differentiator if approved. Phase 2b data is expected. |
|
Roche / Zealand Pharma |
Survodutide |
Dual agonist therapy in the pre-approval stage with a growing pipeline focus. |
Beyond Weight Loss — Emerging GLP-1 Indications Expanding the Market
The commercial opportunity for GLP-1 drugs is now expanding far beyond obesity treatment. Wegovy gained major attention after semaglutide showed a 20% reduction in major cardiovascular events in the 2023 SELECT trial. The therapy is now FDA-approved for cardiovascular risk reduction.
GLP-1 therapies are also being studied for non-alcoholic steatohepatitis (NASH/MASH), an area with more than 115 million patients globally and very limited treatment options. Chronic kidney disease is another growing focus area. Early clinical data suggests GLP-1 drugs may help slow kidney disease progression in diabetic patients.
Scientists are also studying uses for addiction treatment. Early research is also opening up new possibilities in addiction treatment. Some studies suggest GLP-1 therapies may support lower cravings for alcohol and opioids. In 2024, Zepbound received FDA approval for obstructive sleep apnea. As new clinical applications continue to emerge, current GLP-1 market estimates may still underestimate the market’s long-term commercial potential.
Strategic Implications for Pharma, Biotech & Healthcare Investors
For pharmaceutical companies, the current market environment is creating a major opportunity for pipeline expansion. Investment in GLP-1 combinations and next-generation formulations, including oral, weekly, and monthly therapies, is increasing as competition intensifies. The current market window may not remain this open for long.
For biotech companies, partnership and licensing activity with larger pharmaceutical players continues to grow. Specialty indications such as NASH, addiction treatment, and renal disease are creating new differentiation opportunities. These areas are less crowded than the obesity market.
Budget planning also faces growing pressure on healthcare systems and payers. Increased GLP-1 coverage could support lower long-term healthcare costs associated with cardiovascular events and hospitalizations. At the same time, near-term drug spending could rise sharply.
Device manufacturers are also seeing market shifts. Growing GLP-1 adoption is reducing demand for bariatric surgery devices, creating a potential headwind for the sector.
Polaris Market Research tracks the full GLP-1 value chain, from API manufacturing to payer dynamics. Access our Pharmaceuticals Market Reports for strategic intelligence.
Conclusion — A Market That Is Still in Its First Inning
GLP-1 drugs are no longer seen as a short-term healthcare trend. The market is becoming a long-term commercial opportunity across obesity, diabetes, cardiovascular care, and other chronic diseases. The next phase of competition will focus on oral formulations, once-monthly dosing, and combination therapies between 2026 and 2030. As demand and pipeline activity continue to grow, companies are reshaping long-term strategies across the pharmaceutical value chain.
Explore Polaris Market Research’s Pharmaceuticals industry coverage and GLP-1/anti-obesity market reports for deeper strategic insights.
FAQs
How big is the GLP-1 drug market in 2025?
The global anti-obesity medication market was valued at USD 52.82 billion in 2025.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide. Ozempic is mainly for Type 2 diabetes, while Wegovy is approved for obesity and weight management.
Which companies are leading the GLP-1 market?
Novo Nordisk and Eli Lilly are leading the GLP-1 market with drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.
What are GLP-1 drugs approved for beyond diabetes?
They are also approved for obesity, cardiovascular risk reduction, and obstructive sleep apnea.
Will GLP-1 drug prices come down in the next 5 years?
Prices may decline as production expands and more competitors enter the market.
